Drug Trial Radar · NCT02324452
Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines
Last checked: Nov 19, 2026Latest source record: May 11, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,103
Actual
Start
Mar 2015
Primary completion
Jan 2018
Study completion Mar 2018
Sponsor
- Lead sponsor
- The Netherlands Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 24, 2014
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study it will be determined whether the rate of severe toxicity associated with fluoropyrimidine treatment (capecitabine or 5-fluorouracil) can be significantly diminished by individualized dosing of fluoropyrimidines based on upfront genotypic assessment of dihydropyrimidine dehydrogenase (DPD) deficiency. In addition to the genotyping, the DPD phenotype of all patients will be determined by measuring the baseline dihydrouracil/uracil (DHU/U) ratio, in order to investigate whether phenotype-guided treatment can further improve patient safety. In a subgroup of patients, other phenotyping methods will be tested: measuring the plasma levels of uracil after a uracil test dose and a uracil breath test after a dose of \[2-13C\] -labeled uracil. To validate these tests, these phenotyping results will be compared with the results of a DPD activity assay (which measures DPD enzyme activity in peripheral blood mononuclear cells), which is considered the gold standard in measuring DPD phenotype.
Conditions
- Neoplasms
Interventions
Fluoropyrimidine (capecitabine or 5-fluorouracil)Drug
Patient that are a heterozygous carrier of a DPYD variant will receive a reduced dosage of capecitabine or 5-fluorouracil (25-50% reduction, depending on which SNP is identified). The dose will be titrated in subsequent cycles, to achieve maximal safe exposure. Patients that are wild type (not carrying any of the for DPYD variants) will receive a normal (full) dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: incidence of severe treatment-related toxicity (CTC grade 3 to 5)Time frame: patients will be followed during fluoropyrimidine treatment, expected average of 1 year
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
Amsterdam, Netherlands
Wilhelmina Hospital Assen
Assen, Netherlands
Amphia Hospital
Breda, Netherlands
Reinier de Graaf Hospital
Delft, Netherlands
Deventer Hospital
Deventer, Netherlands
Hospital Gelderse Vallei
Ede, Netherlands
Catharina Hospital
Eindhoven, Netherlands
Leiden University Medical Center
Leiden, Netherlands
Maastricht University Medical Center
Maastricht, Netherlands
Canisius-Wilhelmina Hospital
Nijmegen, Netherlands
Laurentius Hospital
Roermond, Netherlands
Bravis Hospital
Roosendaal, Netherlands
Erasmus MC
Rotterdam, Netherlands
Franciscus Gasthuis & Vlietland
Rotterdam, Netherlands
Haga Hospital
The Hague, Netherlands
Medical Center Haaglanden
The Hague, Netherlands
University Medical Center Utrecht
Utrecht, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.